Strategies to treat autoimmune diabetes

References

• Eisenbarth GS. Type I diabetes mellitus. A chronic autoimmune disease. N. Engl. J. Med.314(21), 1360–1368 (1986).
   PubMed Web of Science ®Google Scholar
• Verge CF, Gianani R, Kawasaki E et al. Prediction of Type I diabetes in first-degree relatives using a combination of insulin, GAD, and ICA512bdc/IA-2 autoantibodies. Diabetes45(7), 926–933 (1996).
   PubMed Web of Science ®Google Scholar
• Yu L, Robles DT, Abiru N et al. Early expression of anti-insulin autoantibodies of humans and the NOD mouse: evidence for early determination of subsequent diabetes. Proc. Natl Acad. Sci. USA97(4), 1701–1706 (2000).
   PubMed Web of Science ®Google Scholar
• Trudeau JD, Kelly-Smith C, Verchere CB et al. Prediction of spontaneous autoimmune diabetes in NOD mice by quantification of autoreactive T cells in peripheral blood. J. Clin. Invest.111(2), 217–223 (2003).
   PubMed Web of Science ®Google Scholar
• Yang ZD, Chen M, Wu R, McDuffie M, Nadler JL. The anti-inflammatory compound lisofylline prevents Type I diabetes in non-obese diabetic mice. Diabetologia45(9), 1307–1314 (2002).
   PubMed Web of Science ®Google Scholar
• Yang Z, Chen M, Fialkow LB, Ellett JD, Wu R, Nadler JL. The novel anti-inflammatory compound, lisofylline, prevents diabetes in multiple low-dose streptozotocin-treated mice. Pancreas26(4), E99–E104 (2003).
   PubMedGoogle Scholar
• Yang Z, Chen M, Ellett JD, Fialkow LB, Carter JD, Nadler JL. The novel anti-inflammatory agent lisofylline prevents autoimmune diabetic recurrence after islet transplantation. Transplantation77(1), 55–60 (2004).
   PubMed Web of Science ®Google Scholar
• Yang Z, Chen M, Carter JD et al. Combined treatment with lisofylline and exendin-4 reverses autoimmune diabetes. Biochem. Biophys. Res. Commun.344(3), 1017–1022 (2006).
   PubMed Web of Science ®Google Scholar
• Like AA, Rossini AA, Guberski DL, Appel MC, Williams RM. Spontaneous diabetes mellitus: reversal and prevention in the BB/W rat with antiserum to rat lymphocytes. Science206(4425), 1421–1423 (1979).
   PubMed Web of Science ®Google Scholar
• Ogawa N, Minamimura K, Kodaka T, Maki T. Short administration of polyclonal anti-T cell antibody (ALS) in NOD mice with extensive insulitis prevents subsequent development of autoimmune diabetes. J. Autoimmun.26(4), 225–231 (2006).
   PubMed Web of Science ®Google Scholar
• Maki T, Ichikawa T, Blanco R, Porter J. Long-term abrogation of autoimmune diabetes in nonobese diabetic mice by immunotherapy with anti-lymphocyte serum. Proc. Natl Acad. Sci. USA89(8), 3434–3438 (1992).
   PubMed Web of Science ®Google Scholar
• Ogawa N, List JF, Habener JF, Maki T. Cure of overt diabetes in NOD mice by transient treatment with anti-lymphocyte serum and exendin-4. Diabetes53(7), 1700–1705 (2004).
   PubMed Web of Science ®Google Scholar
• Stegall MD, Kim DY, Prieto M et al. Thymoglobulin induction decreases rejection in solitary pancreas transplantation. Transplantation72(10), 1671–1675 (2001).
   Google Scholar
• Chatenoud L, Thervet E, Primo J, Bach JF. Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc. Natl Acad. Sci. USA91(1), 123–127 (1994).
   PubMed Web of Science ®Google Scholar
• Ferran C, Sheehan K, Dy M et al. Cytokine-related syndrome following injection of anti-CD3 monoclonal antibody: further evidence for transient in vivo T cell activation. Eur. J. Immunol.20(3), 509–515 (1990).
   PubMed Web of Science ®Google Scholar
• Alegre M, Vandenabeele P, Flamand V et al. Hypothermia and hypoglycemia induced by anti-CD3 monoclonal antibody in mice: role of tumor necrosis factor. Eur. J. Immunol.20(3), 707–710 (1990).
   PubMed Web of Science ®Google Scholar
• Abramowicz D, Schandene L, Goldman M et al. Release of tumor necrosis factor, interleukin-2, and γ-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients. Transplantation47(4), 606–608 (1989).
   PubMed Web of Science ®Google Scholar
• Keymeulen B, Vandemeulebroucke E, Ziegler AG et al. Insulin needs after CD3-antibody therapy in new-onset Type 1 diabetes. N. Engl. J. Med.352(25), 2598–2608 (2005).
   PubMed Web of Science ®Google Scholar
• Belghith M, Bluestone JA, Barriot S, Megret J, Bach JF, Chatenoud L. TGF-β-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat. Med.9(9), 1202–1208 (2003).
   PubMed Web of Science ®Google Scholar
• Herold KC, Gitelman SE, Masharani U et al. A single course of anti-CD3 monoclonal antibody hOKT3γ1(Ala–Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of Type 1 diabetes. Diabetes54(6), 1763–1769 (2005).
   PubMed Web of Science ®Google Scholar
• Herold KC, Burton JB, Francois F, Poumian-Ruiz E, Glandt M, Bluestone JA. Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3γ1(Ala–Ala). J. Clin. Invest.111(3), 409–418 (2003).
   PubMed Web of Science ®Google Scholar
• Bisikirska B, Colgan J, Luban J, Bluestone JA, Herold KC. TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs. J. Clin. Invest.115(10), 2904–2913 (2005).
   PubMed Web of Science ®Google Scholar
• van de Linde P, Tysma OM, Medema JP et al. Mechanisms of antibody immunotherapy on clonal islet reactive T cells. Hum. Immunol.67(4–5), 264–273 (2006).
   PubMed Web of Science ®Google Scholar
• Greeley SA, Katsumata M, Yu L et al. Elimination of maternally transmitted autoantibodies prevents diabetes in nonobese diabetic mice. Nat. Med.8(4), 399–402 (2002).
   PubMed Web of Science ®Google Scholar
• Koczwara K, Bonifacio E, Ziegler AG. Transmission of maternal islet antibodies and risk of autoimmune diabetes in offspring of mothers with Type 1 diabetes. Diabetes53(1), 1–4 (2004).
   PubMed Web of Science ®Google Scholar
• Silveira PA, Grey ST. B cells in the spotlight: innocent bystanders or major players in the pathogenesis of Type 1 diabetes. Trends Endocrinol. Metab.17(4), 128–135 (2006).
   PubMed Web of Science ®Google Scholar
• Noorchashm H, Noorchashm N, Kern J, Rostami SY, Barker CF, Naji A. β-cells are required for the initiation of insulitis and sialitis in nonobese diabetic mice. Diabetes46(6), 941–946 (1997).
   PubMed Web of Science ®Google Scholar
• Noorchashm H, Lieu YK, Noorchashm N et al. I-Ag7-mediated antigen presentation by B lymphocytes is critical in overcoming a checkpoint in T cell tolerance to islet β cells of nonobese diabetic mice. J. Immunol.163(2), 743–750 (1999).
   PubMed Web of Science ®Google Scholar
• Hulbert C, Riseili B, Rojas M, Thomas JW. β cell specificity contributes to the outcome of diabetes in nonobese diabetic mice. J. Immunol.167(10), 5535–5538 (2001).
   PubMed Web of Science ®Google Scholar
• Martin S, Wolf-Eichbaum D, Duinkerken G et al. Development of Type 1 diabetes despite severe hereditary B-lymphocyte deficiency. N. Engl. J. Med.345(14), 1036–1040 (2001).
   PubMed Web of Science ®Google Scholar
• Redondo MJ, Eisenbarth GS. Genetic control of autoimmunity in Type I diabetes and associated disorders. Diabetologia45(5), 605–622 (2002).
   PubMedGoogle Scholar
• Radosevic K, Casteels KM, Mathieu C, Van Ewijk W, Drexhage HA, Leenen PJ. Splenic dendritic cells from the non-obese diabetic mouse induce a prolonged proliferation of syngeneic T cells. A role for an impaired apoptosis of NOD T cells? J. Autoimmun.13(4), 373–382 (1999).
   Google Scholar
• Feili-Hariri M, Morel PA. Phenotypic and functional characteristics of BM-derived DC from NOD and non-diabetes-prone strains. Clin. Immunol.98(1), 133–142 (2001).
   PubMed Web of Science ®Google Scholar
• Takahashi K, Honeyman MC, Harrison LC. Impaired yield, phenotype, and function of monocyte-derived dendritic cells in humans at risk for insulin-dependent diabetes. J. Immunol.161(5), 2629–2635 (1998).
   PubMed Web of Science ®Google Scholar
• Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu. Rev. Immunol.21, 685–711 (2003).
   PubMed Web of Science ®Google Scholar
• Clare-Salzler MJ, Brooks J, Chai A, Van Herle K, Anderson C. Prevention of diabetes in nonobese diabetic mice by dendritic cell transfer. J. Clin. Invest.90(3), 741–748 (1992).
   PubMed Web of Science ®Google Scholar
• Feili-Hariri M, Dong X, Alber SM, Watkins SC, Salter RD, Morel PA. Immunotherapy of NOD mice with bone marrow-derived dendritic cells. Diabetes48(12), 2300–2308 (1999).
   PubMed Web of Science ®Google Scholar
• Feili-Hariri M, Falkner DH, Morel PA. Regulatory Th2 response induced following adoptive transfer of dendritic cells in prediabetic NOD mice. Eur. J. Immunol.32(7), 2021–2030 (2002).
   PubMed Web of Science ®Google Scholar
• Haase C, Ejrnaes M, Juedes AE, Wolfe T, Markholst H, von Herrath MG. Immunomodulatory dendritic cells require autologous serum to circumvent nonspecific immunosuppressive activity in vivo. Blood106(13), 4225–4233 (2005).
   Google Scholar
• Morin J, Faideau B, Gagnerault MC, Lepault F, Boitard C, Boudaly S. Passive transfer of flt-3L-derived dendritic cells delays diabetes development in NOD mice and associates with early production of interleukin (IL)-4 and IL-10 in the spleen of recipient mice. Clin. Exp. Immunol.134(3), 388–395 (2003).
   PubMed Web of Science ®Google Scholar
• Menges M, Rossner S, Voigtlander C et al. Repetitive injections of dendritic cells matured with tumor necrosis factor α induce antigen-specific protection of mice from autoimmunity. J. Exp. Med.195(1), 15–21 (2002).
   PubMed Web of Science ®Google Scholar
• Verginis P, Li HS, Carayanniotis G. Tolerogenic semimature dendritic cells suppress experimental autoimmune thyroiditis by activation of thyroglobulin-specific CD4+CD25+ T cells. J. Immunol.174(11), 7433–7439 (2005).
   PubMed Web of Science ®Google Scholar
• Tang Q, Henriksen KJ, Bi M et al.In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J. Exp. Med.199(11), 1455–1465 (2004).
   PubMed Web of Science ®Google Scholar
• Tarbell KV, Yamazaki S, Olson K, Toy P, Steinman RM. CD25+ CD4+ T cells, expanded with dendritic cells presenting a single autoantigenic peptide, suppress autoimmune diabetes. J. Exp. Med.199(11), 1467–1477 (2004).
   PubMed Web of Science ®Google Scholar
• Yamazaki S, Iyoda T, Tarbell K et al. Direct expansion of functional CD25+ CD4+ regulatory T cells by antigen-processing dendritic cells. J. Exp. Med.198(2), 235–247 (2003).
   PubMed Web of Science ®Google Scholar
• Fisson S, Djelti F, Trenado A et al. Therapeutic potential of self-antigen-specific CD4+CD25+ regulatory T cells selected in vitro from a polyclonal repertoire. Eur. J. Immunol.36(4), 817–827 (2006).
   Google Scholar
• Ebner S, Hofer S, Nguyen VA et al. A novel role for IL-3: human monocytes cultured in the presence of IL-3 and IL-4 differentiate into dendritic cells that produce less IL-12 and shift Th cell responses toward a Th2 cytokine pattern. J. Immunol.168(12), 6199–6207 (2002).
   PubMed Web of Science ®Google Scholar
• Macatonia SE, Doherty TM, Knight SC, O’Garra A. Differential effect of IL-10 on dendritic cell-induced T cell proliferation and IFN-γ production. J. Immunol.150(9), 3755–3765 (1993).
   PubMedGoogle Scholar
• Sakaguchi S, Fukuma K, Kuribayashi K, Masuda T. Organ-specific autoimmune diseases induced in mice by elimination of T cell subset. I. Evidence for the active participation of T cells in natural self-tolerance; deficit of a T cell subset as a possible cause of autoimmune disease. J. Exp. Med.161(1), 72–87 (1985).
   PubMed Web of Science ®Google Scholar
• Danke NA, Koelle DM, Yee C, Beheray S, Kwok WW. Autoreactive T cells in healthy individuals. J. Immunol.172(10), 5967–5972 (2004).
   PubMed Web of Science ®Google Scholar
• Pop SM, Wong CP, Culton DA, Clarke SH, Tisch R. Single cell analysis shows decreasing FoxP3 and TGFβ1 coexpressing CD4+CD25+ regulatory T cells during autoimmune diabetes. J. Exp. Med.201(8), 1333–1346 (2005).
   PubMed Web of Science ®Google Scholar
• Lindley S, Dayan CM, Bishop A, Roep BO, Peakman M, Tree TI. Defective suppressor function in CD4+CD25+ T-cells from patients with Type 1 diabetes. Diabetes54(1), 92–99 (2005).
   PubMed Web of Science ®Google Scholar
• Kukreja A, Cost G, Marker J et al. Multiple immuno-regulatory defects in Type-1 diabetes. J. Clin. Invest.109(1), 131–140 (2002).
   PubMed Web of Science ®Google Scholar
• Daniel D, Wegmann DR. Protection of nonobese diabetic mice from diabetes by intranasal or subcutaneous administration of insulin peptide B-(9–23). Proc. Natl Acad. Sci. USA93(2), 956–960 (1996).
   PubMed Web of Science ®Google Scholar
• Bergerot I, Arreaza GA, Cameron MJ et al. Insulin B-chain reactive CD4+ regulatory T-cells induced by oral insulin treatment protect from Type 1 diabetes by blocking the cytokine secretion and pancreatic infiltration of diabetogenic effector T-cells. Diabetes48(9), 1720–1729 (1999).
   PubMed Web of Science ®Google Scholar
• Ploix C, Bergerot I, Fabien N, Perche S, Moulin V, Thivolet C. Protection against autoimmune diabetes with oral insulin is associated with the presence of IL-4 Type 2 T-cells in the pancreas and pancreatic lymph nodes. Diabetes47(1), 39–44 (1998).
   PubMedGoogle Scholar
• Polanski M, Melican NS, Zhang J, Weiner HL. Oral administration of the immunodominant B-chain of insulin reduces diabetes in a co-transfer model of diabetes in the NOD mouse and is associated with a switch from Th1 to Th2 cytokines. J. Autoimmun.10(4), 339–346 (1997).
   PubMed Web of Science ®Google Scholar
• Homann D, Dyrberg T, Petersen J, Oldstone MB, von Herrath MG. Insulin in oral immune ‘tolerance’ a one-amino acid change in the B chain makes the difference. J. Immunol.163(4), 1833–1838 (1999).
   PubMed Web of Science ®Google Scholar
• Diabetes Prevention Trial – Type 1 Diabetes Study Group. Effects of insulin in relatives of patients with Type 1 diabetes mellitus. N. Engl. J. Med.346(22), 1685–1691 (2002).
   PubMed Web of Science ®Google Scholar
• Harrison LC, Dempsey-Collier M, Kramer DR, Takahashi K. Aerosol insulin induces regulatory CD8 γ δ T cells that prevent murine insulin-dependent diabetes. J. Exp. Med.184(6), 2167–2174 (1996).
   PubMedGoogle Scholar
• Harrison LC, Honeyman MC, Steele CE et al. Pancreatic β-cell function and immune responses to insulin after administration of intranasal insulin to humans at risk for Type 1 diabetes. Diabetes Care27(10), 2348–2355 (2004).
   PubMed Web of Science ®Google Scholar
• Pozzilli P, Pitocco D, Visalli N et al. No effect of oral insulin on residual β-cell function in recent-onset Type I diabetes (the IMDIAB VII). IMDIAB Group. Diabetologia43(8), 1000–1004 (2000).
   PubMed Web of Science ®Google Scholar
• Ploix C, Bergerot I, Durand A, Czerkinsky C, Holmgren J, Thivolet C. Oral administration of cholera toxin β-insulin conjugates protects NOD mice from autoimmune diabetes by inducing CD4+ regulatory T-cells. Diabetes48(11), 2150–2156 (1999).
   PubMedGoogle Scholar
• Petersen JS, Bregenholt S, Apostolopolous V et al. Coupling of oral human or porcine insulin to the B subunit of cholera toxin (CTB) overcomes critical antigenic differences for prevention of Type I diabetes. Clin. Exp. Immunol.134(1), 38–45 (2003).
   PubMedGoogle Scholar
• Alleva DG, Gaur A, Jin L et al. Immunological characterization and therapeutic activity of an altered-peptide ligand, NBI-6024, based on the immunodominant Type 1 diabetes autoantigen insulin B-chain (9–23) peptide. Diabetes51(7), 2126–2134 (2002).
   PubMed Web of Science ®Google Scholar
• Alleva DG, Maki RA, Putnam AL et al. Immunomodulation in Type 1 diabetes by NBI-6024, an altered peptide ligand of the insulin B epitope. Scand J. Immunol.63(1), 59–69 (2006).
   PubMed Web of Science ®Google Scholar
• Coon B, An LL, Whitton JL, von Herrath MG. DNA immunization to prevent autoimmune diabetes. J. Clin. Invest.104(2), 189–194 (1999).
   PubMed Web of Science ®Google Scholar
• Bot A, Smith D, Bot S et al. Plasmid vaccination with insulin B chain prevents autoimmune diabetes in nonobese diabetic mice. J. Immunol.167(5), 2950–2955 (2001).
   PubMed Web of Science ®Google Scholar
• Raz I, Elias D, Avron A, Tamir M, Metzger M, Cohen IR. β-cell function in new-onset Type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, Phase II trial. Lancet358(9295), 1749–1753 (2001).
   PubMed Web of Science ®Google Scholar
• Zanin-Zhorov A, Nussbaum G, Franitza S, Cohen IR, Lider O. T cells respond to heat shock protein 60 via TLR2: activation of adhesion and inhibition of chemokine receptors. FASEB J.17(11), 1567–1569 (2003).
   PubMed Web of Science ®Google Scholar
• Bowman M, Atkinson MA. Heat shock protein therapy fails to prevent diabetes in NOD mice. Diabetologia45(9), 1350–1351 (2002).
   PubMed Web of Science ®Google Scholar
• Elias D, Cohen IR. Treatment of autoimmune diabetes and insulitis in NOD mice with heat shock protein 60 peptide p277. Diabetes44(9), 1132–1138 (1995).
   PubMed Web of Science ®Google Scholar
• Lazar L, Ofan R, Weintrob N et al. Heat-shock protein peptide DiaPep277 treatment in children with newly diagnosed Type 1 diabetes: a randomised, double-blind Phase II study. Diabetes Metab. Res. Rev. (2006) (Epub ahead of print).
   Google Scholar
• Huurman VA, Decochez K, Mathieu C, Cohen IR, Roep BO. Therapy with the hsp60 peptide DiaPep277™ in C-peptide positive Type 1 diabetes patients. Diabetes Metab. Res. Rev. (2006) (Epub ahead of print).
   Google Scholar
• Kaufman DL, Clare-Salzler M, Tian J et al. Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes. Nature366(6450), 69–72 (1993).
   PubMed Web of Science ®Google Scholar
• Tisch R, Yang XD, Singer SM, Liblau RS, Fugger L, McDevitt HO. Immune response to glutamic acid decarboxylase correlates with insulitis in non-obese diabetic mice. Nature366(6450), 72–75 (1993).
   PubMed Web of Science ®Google Scholar
• Jaeckel E, Klein L, Martin-Orozco N, von Boehmer H. Normal incidence of diabetes in NOD mice tolerant to glutamic acid decarboxylase. J. Exp. Med.197(12), 1635–1644 (2003).
   PubMed Web of Science ®Google Scholar
• Nakayama M, Abiru N, Moriyama H et al. Prime role for an insulin epitope in the development of Type 1 diabetes in NOD mice. Nature435(7039), 220–223 (2005).
   PubMed Web of Science ®Google Scholar
• Petersen JS, Karlsen AE, Markholst H, Worsaae A, Dyrberg T, Michelsen B. Neonatal tolerization with glutamic acid decarboxylase but not with bovine serum albumin delays the onset of diabetes in NOD mice. Diabetes43(12), 1478–1484 (1994).
   PubMedGoogle Scholar
• Pleau JM, Fernandez-Saravia F, Esling A, Homo-Delarche F, Dardenne M. Prevention of autoimmune diabetes in nonobese diabetic female mice by treatment with recombinant glutamic acid decarboxylase (GAD 65). Clin. Immunol. Immunopathol.76(1 Pt 1), 90–95 (1995).
   PubMedGoogle Scholar
• Tian J, Atkinson MA, Clare-Salzler M et al. Nasal administration of glutamate decarboxylase (GAD65) peptides induces Th2 responses and prevents murine insulin-dependent diabetes. J. Exp. Med.183(4), 1561–1567 (1996).
   PubMed Web of Science ®Google Scholar
• Agardh CD, Cilio CM, Lethagen A et al. Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes. J. Diabetes Complications19(4), 238–246 (2005).
   PubMed Web of Science ®Google Scholar
• Herold KC, Hagopian W, Auger JA et al. Anti-CD3 monoclonal antibody in new-onset Type 1 diabetes mellitus. N. Engl. J. Med.346(22), 1692–1698 (2002).
   PubMed Web of Science ®Google Scholar
• Gutniak M, Orskov C, Holst JJ, Ahren B, Efendic S. Antidiabetogenic effect of glucagon-like peptide-1 (7–36)amide in normal subjects and patients with diabetes mellitus. N. Engl. J. Med.326(20), 1316–1322 (1992).
   PubMed Web of Science ®Google Scholar
• Bresson D, Togher L, Rodrigo E et al. Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs. J. Clin. Invest.116(5), 1371–1381 (2006).
   PubMed Web of Science ®Google Scholar